CompletedNCT01174355
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
This study evaluated the safety and effectiveness of ND0801 for people with ADHD.
Medication studyAges 18–55Israel
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of ND0801 for people with ADHD.
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Haifa and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateOctober 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- NeuroDerm Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Israel
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT01174355
- Official title
Show the full official title
A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
Get this study by email
Recruitment & locations
CompletedHaifa · Hod HaSharon
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of ND0801 for people with ADHD.
Who is behind this study?
The study sponsor is NeuroDerm Ltd.
Did this study involve medication?
Yes. The study involved medication, including ND0801.
Who was this study for?
Listed age limits: 18 years to 55 years.
